Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

Share

.2016 Feb 1;213(3):379-85.
doi: 10.1093/infdis/jiv327. Epub 2015 Jun 10.

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin

Affiliations

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin

Susan E Maslanka et al. J Infect Dis..

Abstract

Botulism is a potentially fatal paralytic disease caused by the action of botulinum neurotoxin (BoNT) on nerve cells. There are 7 known serotypes (A-G) of BoNT and up to 40 genetic variants. Clostridium botulinum strain IBCA10-7060 was recently reported to produce BoNT serotype B (BoNT/B) and a novel BoNT, designated as BoNT/H. The BoNT gene (bont) sequence of BoNT/H was compared to known bont sequences. Genetic analysis suggested that BoNT/H has a hybrid-like structure containing regions of similarity to the structures of BoNT/A1 and BoNT/F5. This novel BoNT was serologically characterized by the mouse neutralization assay and a neuronal cell-based assay. The toxic effects of this hybrid-like BoNT were completely eliminated by existing serotype A antitoxins, including those contained in multivalent therapeutic antitoxin products that are the mainstay of human botulism treatment.

Keywords: Clostridium botulinum; botulinum toxin; botulism; neuronal cell-based assay; neutralization; serotype.

Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A andC, Nucleotide similarity plots (derived from SimPlot [7]) are shown for the novelbont/FA (A) and the previously recognizedbont/CD (C). The percentage similarity was generated using a 200-bp window and a 20-bp step.A,bont/A1 (green) andbont/F5 (red) are shown withbont/FA (individual nucleotide data were obtained from GenBank accession numbers AM412317 [forbont/A1], GU213212 [forbont/F5], and JSCF00000000 [forbont/FA]).B,bont/D (green) andbont/C (red) are shown withbont/CD (individual nucleotide data were obtained from GenBank accession numbers JENR01000128 [forbont/D], AB200358 [forbont/C], and AB200360 [forbont/CD]). The gene regions encoding the 3 domains (light chain [LC], N-terminal heavy chain [HCN], and C-terminal heavy chain [HCC]) are indicated by dotted lines.B andD, The predicted amino acid identity of botulinum neurotoxin (BoNT) LC, HCN, and HCC domains are for the hybrid toxins BoNT F/A (B) and BoNT C/D (D). Domains sharing ≥80% amino acid identity in pairwise alignments between the associated hybrid toxins and the comparison toxins are shaded. The percentage amino acid identity of the most similar domains is also indicated. The structure of the novel toxin contained in strain IBCA10-7060 (BoNT F/A) has significant similarity to the LC domain of BoNT/F5 (A) and the HCC domain of BoNT/A1 (B). For comparison, the structure of another hybrid toxin (BoNT C/D) is also shown (C andD).
Figure 2.
Figure 2.
Neutralization of University of Wisconsin–Madison (UW) toxin 2 with heptavalent botulism antitoxin (BAT) in a neuronal cell–based assay. The indicated amounts of extract were incubated without (top) or with 2 µL (bottom) of heptavalent botulism antitoxin, in 100 µL of culture medium and incubated for 1 hour at 37°C. The toxin/BAT mixtures were then added to hiPSC-derived neurons (100 µL/well) and incubated for 24 hours at 37°C in 5% CO2. Cell lysates were prepared in 50 µL of lithium dodecyl sulfate sample buffer (Life Technologies) and analyzed by Western blot for levels of VAMP2, syntaxin, and SNAP-25, as previously described [24, 25]. VAMP-2 remains intact when the culture supernatant is pretreated with BAT, demonstrating a protective capacity.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yu PA, Maslanka SE, St Louis ME, Swerdlow DL. Botulism. In: Abrutyn E, Brachman PS, eds. Bacterial infections in humans. New York: Springer, 2009:159–76.
    1. CDC. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational Botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010; 59:299. - PubMed
    1. FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes [news release]. 2013.http://www.fda.gov/newsEvents/Newsroom/Press/Announcements/ucm345128.htm. Accessed 12 April 2014.
    1. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. New Eng J Med 2005; 354:462–71. - PubMed
    1. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: A clinical and epidemiologic review. Annals of Internal Med 1998; 123:221–8. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp